Do Stimulant Medications Improve Educational and Behavioral Outcomes for Children with ADHD?

Overview

Journal J Health Econ

Specialty Health Services

Date 2014 Jun 24

PMID 24954077

Citations 24

Authors

Janet Currie

Mark Stabile

Lauren Jones

Affiliations

Soon will be listed here.

Abstract

We examine the effects of a policy change in the province of Quebec, Canada which greatly expanded insurance coverage for prescription medications. We show that the change was associated with a sharp increase in the use of stimulant medications commonly prescribed for ADHD in Quebec relative to the rest of Canada. We ask whether this increase in medication use was associated with improvements in emotional functioning or academic outcomes among children with ADHD. We find little evidence of improvement in either the medium or the long run. Our results are silent on the effects on optimal use of medication for ADHD, but suggest that expanding medication in a community setting had little positive benefit and may have had harmful effects given the average way these drugs are used in the community.

Citing Articles

Differential costs for the non-adult ADHD population in Catalonia.

Mora T, Puig-Junoy J, Jacobs R, Cid J Health Econ Rev. 2023; 13(1):24.

PMID: 37086372 PMC: 10122377. DOI: 10.1186/s13561-023-00437-8.

ADHD diagnosis and methylphenidate consumption in children and adolescents: A systematic analysis of health databases in France over the period 2010-2019.

Ponnou S, Thome B Front Psychiatry. 2022; 13:957242.

PMID: 36299551 PMC: 9590284. DOI: 10.3389/fpsyt.2022.957242.

The Contributions of Cognitive Abilities to the Relationship between ADHD Symptoms and Academic Achievement.

Tsantilas D, Ilie A, Waldon J, McGonnell M, Corkum P Brain Sci. 2022; 12(8).

PMID: 36009138 PMC: 9406095. DOI: 10.3390/brainsci12081075.

Exploring the Effects of Pharmacological, Psychosocial, and Alternative/Complementary Interventions in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Meta-Regression Approach.

Yang K, Lane H, Chang Y, Tzang R Int J Neuropsychopharmacol. 2021; 24(10):776-786.

PMID: 34086891 PMC: 8538900. DOI: 10.1093/ijnp/pyab034.

Overdiagnosis of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Systematic Scoping Review.

Kazda L, Bell K, Thomas R, McGeechan K, Sims R, Barratt A JAMA Netw Open. 2021; 4(4):e215335.

PMID: 33843998 PMC: 8042533. DOI: 10.1001/jamanetworkopen.2021.5335.

References

Bedard A, Jain U, Johnson S, Tannock R . Effects of methylphenidate on working memory components: influence of measurement. J Child Psychol Psychiatry. 2007; 48(9):872-80. DOI: 10.1111/j.1469-7610.2007.01760.x. View

Evans S, Pelham W, Smith B, Bukstein O, Gnagy E, Greiner A . Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol. 2001; 9(2):163-75. DOI: 10.1037//1064-1297.9.2.163. View

Joshi S . ADHD, growth deficits, and relationships to psychostimulant use. Pediatr Rev. 2002; 23(2):67-8; discussion 67-8. DOI: 10.1542/pir.23-2-67. View

Pomey M, Forest P, Palley H, Martin E . Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec's universal drug insurance program, with comparisons to the Medicare prescription drug program in the United States. Milbank Q. 2007; 85(3):469-98. PMC: 2690320. DOI: 10.1111/j.1468-0009.2007.00496.x. View

. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999; 56(12):1073-86. DOI: 10.1001/archpsyc.56.12.1073. View

Pelham W, Carlson C, Sams S, Vallano G, Dixon M, Hoza B . Separate and combined effects of methylphenidate and behavior modification on boys with attention deficit-hyperactivity disorder in the classroom. J Consult Clin Psychol. 1993; 61(3):506-515. DOI: 10.1037/0022-006X.61.3.506. View

Fletcher J, Wolfe B . Long-term consequences of childhood ADHD on criminal activities. J Ment Health Policy Econ. 2009; 12(3):119-38. PMC: 3398051. View

Currie J, Stabile M . Child mental health and human capital accumulation: the case of ADHD. J Health Econ. 2006; 25(6):1094-118. DOI: 10.1016/j.jhealeco.2006.03.001. View

Cuellar A, Markowitz S . Medicaid policy changes in mental health care and their effect on mental health outcomes. Health Econ Policy Law. 2008; 2(Pt 1):23-49. DOI: 10.1017/S1744133106006268. View

10.

Griffin S, Weatherly H, Richardson G, Drummond M . Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD. Eur J Health Econ. 2007; 9(2):137-45. DOI: 10.1007/s10198-007-0052-7. View

11.

Nissen S . ADHD drugs and cardiovascular risk. N Engl J Med. 2006; 354(14):1445-8. DOI: 10.1056/NEJMp068049. View

12.

Fletcher J, Wolfe B . Child mental health and human capital accumulation: the case of ADHD revisited. J Health Econ. 2008; 27(3):794-800. DOI: 10.1016/j.jhealeco.2007.10.010. View

13.

Scheffler R, Brown T, Fulton B, Hinshaw S, Levine P, Stone S . Positive association between attention-deficit/ hyperactivity disorder medication use and academic achievement during elementary school. Pediatrics. 2009; 123(5):1273-9. DOI: 10.1542/peds.2008-1597. View

14.

Polanczyk G, Silva de Lima M, Horta B, Biederman J, Rohde L . The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007; 164(6):942-8. DOI: 10.1176/ajp.2007.164.6.942. View

15.

Molina B, Hinshaw S, Swanson J, Eugene Arnold L, Vitiello B, Jensen P . The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009; 48(5):484-500. PMC: 3063150. DOI: 10.1097/CHI.0b013e31819c23d0. View

16.

Schachter H, Pham B, King J, Langford S, Moher D . How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2002; 165(11):1475-88. PMC: 81663. View

17.

. Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder--United States, 2003. MMWR Morb Mortal Wkly Rep. 2005; 54(34):842-7. View

18.

Nagin D, Tremblay R . Trajectories of boys' physical aggression, opposition, and hyperactivity on the path to physically violent and nonviolent juvenile delinquency. Child Dev. 1999; 70(5):1181-96. DOI: 10.1111/1467-8624.00086. View

19.

Barbaresi W, Katusic S, Colligan R, Weaver A, Jacobsen S . Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr. 2007; 28(4):274-87. DOI: 10.1097/DBP.0b013e3180cabc28. View

20.

Zoega H, Rothman K, Huybrechts K, Olafsson O, Baldursson G, Almarsdottir A . A population-based study of stimulant drug treatment of ADHD and academic progress in children. Pediatrics. 2012; 130(1):e53-62. DOI: 10.1542/peds.2011-3493. View